Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12 2023 - 3:45PM
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, today announced that
Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore,
Indegene Senior Vice President, Emerging Biotech, will participate
in a live Benzinga All Access event on Monday May 15, 2023, at 10
a.m. CST.
The discussion will focus on the recent announcement of a joint
commercialization agreement between Cingulate and Indegene, a
life sciences commercialization company, to provide commercial
support for Cingulate’s lead candidate CTx-1301
(dexmethylphenidate), a novel, investigational treatment being
developed as a true, once-daily stimulant medication for attention
deficit/hyperactivity disorder (ADHD), upon approval from the U.S.
Food and Drug Administration (FDA).
The event may be viewed live on Benzinga’s YouTube
channel, Benzinga All Access, and will also
be available for viewing on Cingulate’s website
at cingulate.com/investors.
About
Cingulate® Cingulate Inc. (NASDAQ:
CING), is a clinical-stage biopharmaceutical company utilizing its
proprietary Precision Timed Release™ (PTR™) drug delivery platform
technology to build and advance a pipeline of next-generation
pharmaceutical products, designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by
burdensome daily dosing regimens and suboptimal treatment outcomes.
With an initial focus on the treatment of Attention
Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and
evaluating additional therapeutic areas where PTR technology may be
employed to develop future product candidates, including to treat
anxiety disorders. Cingulate is headquartered in Kansas City. For
more information visit Cingulate.com
About IndegeneWe are a digital-first, life
sciences commercialization company. We help biopharmaceutical,
emerging biotech and medical device companies develop products, get
them to the market, and grow their impact through the life cycle in
a more effective, efficient, and modern way. We bring together
healthcare domain expertise, fit-for-purpose technology, and an
agile operating model to provide a diverse range of solutions.
These aim to deliver, amongst other outcomes, a personalized,
scalable and omnichannel experience for patients and physicians.
It’s what drives our team and our purpose to enable healthcare
organizations to be future ready. To learn more, please
visit www.indegene.com
Investor Relations Thomas Dalton Vice
President, Investor & Public Relations,
Cingulatetdalton@cingulate.com913-942-2301
Matt KrepsDarrow Associatesmkreps@darrowir.com214-597-8200
Media RelationsMelyssa WeibleElixir Health
Public Relationsmweible@elixirhealthpr.com201-723-5805
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024